SEPTIN3 and malignant colon neoplasm: Accordingly, both technologies reported the overexpression of STIM1, MBP, SEPTIN9, and SEPTIN10 and the downregulation of CRACR2A, ORMDL3, SARAF, SEPTIN3, and SEPTIN6 in colon cancer cells.